Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN

User menu

  • Subscribe
  • My alerts
  • My Cart
  • Log in

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN
  • Subscribe
  • My alerts
  • My Cart
  • Log in
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Treatment of septic arthritis

Raheem B. Kherani and Kam Shojania
CMAJ October 09, 2007 177 (8) 899-900; DOI: https://doi.org/10.1503/cmaj.1070090
Raheem B. Kherani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kam Shojania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2007 Canadian Medical Association or its licensors

[The authors respond:]

We thank Cheryl Main for her comments on the antimicrobial coverage for both gram-positive and gram-negative septic arthritis that we recommended in our article.1 Our review focused on nongonococcal septic arthritis in patients with pre-existing inflammatory arthritis, and space constraints meant that we could not elaborate on many special circumstances.

Unfortunately, the literature on community-acquired gram-positive septic arthritis in this population is limited. One case series of 59 patients with septic arthritis (in which 15 of the cases were due to MRSA and 44 were not) includes several patients with pre-existing rheumatic disease but does not provide details on the nature of their rheumatic disease.2 The authors of this case series suggest considering empiric treatment for MRSA infection in patients with septic arthritis if there are risk factors such as recent admission to hospital, known infection or colonization with MRSA, multiple comorbidities in addition to the rheumatic disease, injection drug use or residence in communities known to have a high prevalence of community-acquired MRSA infections. These suggestions are consistent with our interpretation of the guidelines referenced by Main.3,4 Hawkes suggests that people of First Nations or African-American heritage, athletes who participate in contact sports, injection drug users, men who have sex with men, military personnel, inmates of correctional facilities, veterinarians, pet owners and pig farmers may be at increased risk of developing MRSA infections.3 As a result, our recommendations continue to be to use cefazolin empirically. For patients known to have risk factors for MRSA infections, vancomycin should be included in the treatment plan until the organism's susceptibility is established.

Although gram-negative infections occur less frequently than gram-positive infections, they are important and potentially difficult to treat. Although it was not the focus of our review, gonococcal septic arthritis should be considered in patients who have demographic risk factors for this condition or in whom Gram's staining does not show bacteria.

Footnotes

  • Competing interests: None declared.

REFERENCES

  1. 1.↵
    Kherani RB, Shojania K. Septic arthritis in patients with pre-existing inflammatory arthritis. CMAJ 2007;176:1605-8.
    OpenUrlFREE Full Text
  2. 2.↵
    Ross JJ, Davidson L. Methicillin-resistant Staphylococcus aureus septic arthritis: an emerging clinical syndrome. Rheumatology 2005;44:1197-8.
    OpenUrlFREE Full Text
  3. 3.↵
    Hawkes M, Barton M, Conly J, et al. Community-acquired MRSA: superbug at our doorstep. CMAJ 2007;176:54-6.
    OpenUrlFREE Full Text
  4. 4.↵
    Barton-Forbes M, Hawkes M, Moore D, et al. Guidelines for the prevention and management of community associated methicillin resistant Staphylococcus aureus (CA-MRSA): a perspective for Canadian health care practitioners. Can J Infect Dis Med Microbiol 2006;17(Suppl C):IB-24B.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 177 (8)
CMAJ
Vol. 177, Issue 8
9 Oct 2007
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatment of septic arthritis
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
Citation Tools
Treatment of septic arthritis
Raheem B. Kherani, Kam Shojania
CMAJ Oct 2007, 177 (8) 899-900; DOI: 10.1503/cmaj.1070090

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Treatment of septic arthritis
Raheem B. Kherani, Kam Shojania
CMAJ Oct 2007, 177 (8) 899-900; DOI: 10.1503/cmaj.1070090
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Scopus
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Avoiding harm to patients: properly calculating costs of harm
  • Continuity of care: the key in telemedicine
  • Open secret: Time of day matters in clinical practice
Show more Letters

Similar Articles

Collections

  • Topics
    • Rheumatology

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Videos
  • Alerts
  • RSS

Information for

  • Advertisers
  • Authors
  • CMA Members
  • Copyright and Permissions
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact

Copyright 2019, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire